{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hydroxychloroquine", "query": { "intervention": "hydroxychloroquine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 194, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hydroxychloroquine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T09:42:07.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01537315", "title": "Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure, Chronic", "Cardiovascular Disease", "Arteriosclerosis" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Matching Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 8, "start_date": "2012-02", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 3, "location_summary": "Little Rock, Arkansas • Gainesville, Florida", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01537315" }, { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" }, { "nct_id": "NCT04345653", "title": "Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Hydroxychloroquine Sulfate (HCQ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 48, "start_date": "2020-04-14", "completion_date": "2021-05-10", "has_results": true, "last_update_posted_date": "2021-05-12", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "Edison, New Jersey", "locations": [ { "city": "Edison", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345653" }, { "nct_id": "NCT01266057", "title": "Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2011-04-28", "completion_date": "2021-02-11", "has_results": false, "last_update_posted_date": "2021-03-04", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266057" }, { "nct_id": "NCT04527549", "title": "Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Dabrafenib mesylate", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Trametinib dimethyl sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-06-01", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 199, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04527549" }, { "nct_id": "NCT04342169", "title": "University of Utah COVID-19 Hydrochloroquine Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronavirus Infection", "Coronavirus", "Infectious Disease" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2020-04-04", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-02-15", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04342169" }, { "nct_id": "NCT01379573", "title": "Preventive Approach to Congenital Heart Block With Hydroxychloroquine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Heart Block", "Neonatal Lupus", "Autoantibody-Associated Heart Block" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 74, "start_date": "2011-01-01", "completion_date": "2020-07-16", "has_results": true, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379573" }, { "nct_id": "NCT04354870", "title": "COVID-19 PrEP HCW HCQ Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Hydroxychloroquine (HCQ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2020-04-03", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04354870" }, { "nct_id": "NCT03428945", "title": "Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type1 Diabetes Mellitus" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 273, "start_date": "2018-08-15", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 37, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 33 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428945" }, { "nct_id": "NCT04458948", "title": "Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-03-24", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-02T09:42:07.886Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458948" } ] }